Is Intellia Therapeutics Stock a Buy?
Intellia Therapeutics (NASDAQ: NTLA) is a biotech company that focuses on gene editing, a relatively new technology that could allow scientists to devise therapies for otherwise impossible-to-treat conditions. As with any new technology, those who invest in it early enough could profit immensely in the long run. The question for investors, though, is whether Intellia is the best company to invest in to benefit from this potentially lucrative market. Let's look at some of the company's most promising programs, as well as its current financial position, to determine whether Intellia's stock is worth buying today.
Intellia currently has about 10 products in its pipeline. The company is going after diseases including hemophilia, a rare condition characterized by abnormal blood clotting, and sickle cell disease (SCD), a disorder that leads to crescent-shaped red blood cells. However, most of Intellia's programs are still very early in their development. Intellia's most advanced pipeline candidate is OTQ923, its potential SCD treatment. Back in March, the U.S. Food and Drug Administration (FDA) approved Intellia's Investigational New Drug (IND) application for OTQ923.
Image source: Getty Images.
Source Fool.com
